Page last updated: 2024-08-24

irinotecan and Sclerosis, Systemic

irinotecan has been researched along with Sclerosis, Systemic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bonnet, F; Contin-Bordes, C; Lapoirie, J; Piazza, L; Tran, L; Truchetet, ME	1

Other Studies

1 other study(ies) available for irinotecan and Sclerosis, Systemic

Article	Year
Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients. Scientific reports, 2021, 09-09, Volume: 11, Issue:1 Topics: Actins; Case-Control Studies; Chemokine CCL2; Collagen Type I; Collagen Type I, alpha 1 Chain; Fibroblasts; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Humans; Irinotecan; Matrix Metalloproteinase 1; Primary Cell Culture; Procollagen; RNA, Messenger; Scleroderma, Systemic; Skin; Topoisomerase I Inhibitors	2021

Article

Year

Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients.

Scientific reports, 2021, 09-09, Volume: 11, Issue:1

Topics: Actins; Case-Control Studies; Chemokine CCL2; Collagen Type I; Collagen Type I, alpha 1 Chain; Fibroblasts; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Humans; Irinotecan; Matrix Metalloproteinase 1; Primary Cell Culture; Procollagen; RNA, Messenger; Scleroderma, Systemic; Skin; Topoisomerase I Inhibitors

2021